By combining long-standing expertise with new research solutions, Charles River advances drug discovery for treatments of respiratory diseases. Our recently validated rodent models provide rapid, cost-effective methods for evaluating the potential efficacy of novel anti-inflammatory agents targeting chronic obstructive pulmonary disease (COPD) or asthma conditions.